Kazia Therapeutics Announces Innovative Clinical Trial
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is thrilled to announce the commencement of an exciting clinical trial that explores a novel treatment strategy for advanced breast cancer. This pioneering study evaluates the efficacy of paxalisib in conjunction with immunotherapy, aiming to provide hope and better treatment options for patients battling this aggressivedisease.
Details of the ABC-Pax Study
The ABC-Pax (Advanced Breast Cancer – Paxalisib) trial is the first of its kind, assessing the combination of paxalisib with KEYTRUDA (pembrolizumab) or LYNPARZA (olaparib) in women experiencing triple-negative breast cancer. This multi-centre, open-label phase 1b study will enroll 24 patients, allowing them to receive this promising combination therapy for up to 12 months.
Research Foundation
The innovative ABC-Pax study originates from critical research conducted by QIMR Berghofer scientists working in conjunction with Kazia Therapeutics. Their research demonstrated that merging paxalisib with immunotherapy can activate a unique molecular program. This approach not only targets dormant cancer cells but also revives immune cells, enabling them to combat the cancer more effectively.
Presenting New Findings
Cool data derived from preclinical models highlighting this treatment combination was recently shared at a prominent breast cancer symposium. These studies exhibited the considerable potential for synergistic effects when paxalisib is used alongside checkpoint inhibitors and other therapeutic agents. Currently, the ABC-Pax trial is accepting participants at the Royal Brisbane and Women's Hospital, with plans to include more locations in Australia.
Kazia's Vision for Breast Cancer Treatment
Kazia's CEO, Dr. John Friend, emphasized the expected transformative impact of this combination therapy for women facing aggressive forms of breast cancer. With enthusiasm, he shared, "The promise of this unique dual treatment strategy could mean a breakthrough in the management of triple-negative breast cancer, and we are proud to support this landmark clinical trial."
Professor Rao's Insights
Professor Sudha Rao from QIMR Berghofer added, "Currently, patients with triple-negative breast cancer often face a grim prognosis with limited treatment options. We aspire to discover new therapies that can enhance the quality and length of life for these patients, potentially extending survival times through innovative treatments that spotlight dormant cancer cells naturally, while also activating the immune defenses necessary to eliminate this disease."
Novel Monitoring Techniques
The ABC-Pax trial aims to incorporate an advanced liquid biopsy digital pathology platform developed by Professor Rao and her team. By analyzing blood samples through this innovative approach, researchers can accurately monitor cancer cell behavior and immune responses in real-time.
A Paradigm Shift in Precision Medicine
Professor Rao explained, "By consistently analyzing the blood samples of participants, we have the opportunity to witness the treatment’s effectiveness as it unfolds. This technique represents a notable advancement in precision medicine, offering a swift and reliable method to track patient progress throughout the course of treatment."
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA) is an Australian oncology-focused drug development firm with a strong commitment to advancing innovative cancer therapies. The focal point of Kazia's endeavors is paxalisib, a promising investigational agent targeting the PI3K/Akt/mTOR pathway, which plays a vital role in various brain cancers. In addition to this, discussions are presently underway about forthcoming studies aimed at refining treatments related to glioblastoma and other brain malignancies.
The company has made measurable progress with ongoing clinical trials targeting brain metastases and other critical conditions, with many reported favorable early data outcomes. With multiple FDA designations enhancing paxalisib’s profile, Kazia is primed to make significant contributions to the medical field.
Frequently Asked Questions
What is the aim of the ABC-Pax study?
The ABC-Pax study aims to evaluate the combination of paxalisib with immunotherapy in women with advanced breast cancer, specifically focusing on triple-negative breast cancer.
Who is leading the clinical trial?
The clinical trial is being led by Kazia Therapeutics in collaboration with QIMR Berghofer scientists.
What innovative tracking method will be used in the trial?
A liquid biopsy digital pathology platform will be used to monitor cancer cell and immune cell behavior in real-time through blood samples.
What is paxalisib?
Paxalisib is an investigational drug that targets the PI3K/Akt/mTOR pathway, which is significant for treating various forms of brain cancer.
How can patients participate in the study?
Patients interested in participating in the ABC-Pax trial can inquire at designated clinical trial sites such as the Royal Brisbane and Women's Hospital, which is currently accepting participants.
